GSK teams up with Merck for new immunotherapy
5th Feb 2019 12:09
(Sharecast News) - GlaxoSmithKline has agreed to pay Germany's Merck up to €3.7bn (£3.2bn) in order to develop a potential cancer treatment.
Read moreGlaxo chairman Philip Hampton stepping down
21st Jan 2019 07:14
(Sharecast News) - GlaxoSmithKline said chairman Sir Philip Hampton was stepping down and the board had started the process to find a successor.
Read moreMonday broker round-up
14th Jan 2019 13:44
(Sharecast News) - Next: Credit Suisse downgrades to underperform with a target price of 4,800p.
Read moreWednesday broker round-up
19th Dec 2018 12:50
(Sharecast News) - Serco Group: Peel Hunt upgrades to hold with a target price of 100p.
Read moreGSK concocts Pfizer consumer health merger and spin-off
19th Dec 2018 07:12
(Sharecast News) - Pharma giants GlaxoSmithKline and Pfizer have struck a deal to combine their consumer health businesses into a joint venture generating £10bn of annual sales, which will later be spun off as a separate listed company.
Read moreWednesday broker round-up
5th Dec 2018 11:18
(Sharecast News) - Ted Baker: HSBC downgrades to hold with a target price of 1,450p.
Read moreGlaxoSmithKline to buy oncology-focused Tesaro for $5.1bn
3rd Dec 2018 12:08
(Sharecast News) - GlaxoSmithKline has agreed to buy US-based oncology-focused pharmaceutical group Tesaro Inc for around $5.1bn (£4bn).
Read moreUnilever agrees £3.1bn Horlicks deal with GSK
3rd Dec 2018 08:41
(Sharecast News) - Unilever has struck a deal to buy Horlicks and other nutrition brands listed in India and Bangladesh from GlaxoSmithKline for roughly £3.1bn.
Read moreGSK says no decision yet made on Horlicks business
29th Nov 2018 11:52
(Sharecast News) - Following reports that it was close to selling its Indian Horlicks business, GlaxoSmithKline on Thursday said only that it is considering a deal.
Read moreUnilever close to buying GSK's Horlicks business - report
28th Nov 2018 08:35
(Sharecast News) - Unilever is in pole position to guzzle up GlaxoSmithKline's Indian Horlicks business and associated nutrition brands for around $4bn, according to reports.
Read moreGSK tightens guidance as new shingles drug boosts earnings
31st Oct 2018 12:27
(Sharecast News) - GlaxoSmithKline tightened up its full year guidance after a strong launch for its new Shingrix shingles vaccine helped the drug maker to a stronger than expected third quarter.
Read moreWednesday preview: BoJ, GlaxoSmithKline and Next in the spotlight
30th Oct 2018 16:23
(Sharecast News) - Barring surprises, the focus on Wednesday will likely be on the Bank of Japan's monetary policy meeting, with traders scanning the headlines for any whiff of any potential near-term shifts in its policy settings.
Read moreGlaxoSmithKline reports encouraging results from HIV drug trial
29th Oct 2018 10:51
(Sharecast News) - Blue chip GlaxoSmithKline said a study into a new HIV drug regime, which could dramatically reduce the number of annual doses required, had been "encouraging".
Read moreMonday broker round-up
8th Oct 2018 13:07
(Sharecast News) - Mediclinic International: Investec upgrades to buy with a target price of 448p.
Read moreGSK's ViiV seeks approval for new one-tablet HIV-1 treatment
14th Sep 2018 09:20
(Sharecast News) - ViiV Healthcare - the HIV specialist majority-owned by GlaxoSmithKline, alongside minority shareholders Pfizer and Shionogi - announced the submission of a marketing authorisation application to the European Medicines Agency on Friday, for a single-tablet, two-drug regimen of dolutegravir and lamivudine for the treatment of the HIV-1 infection.
Read more